Predictors of outcome in patients with unresectable hepatocellular carcinoma receiving transcatheter arterial chemoembolization

H. Shen, D. Agarwal, R. Qi, Naga Chalasani, Suthat Liangpunsakul, L. Lumeng, H. Yoo, P. Kwo

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Transcatheter arterial chemoembolization (TACE) has been shown to improve survival in patients with unresectable hepatocellular carcinoma (HCC). Aim: To identify pretreatment factors that predicts increased mortality in HCC patients receiving TACE. Methods: Retrospective review of all patients who underwent TACE for HCC from January 1999 to November 2004. Patient demographics, aetiology of liver disease, laboratory and imaging data regarding tumour characteristics were obtained. Results: Eighty-eight patients (57 ± 1 years age) received 1-4 sessions of TACE (1.4 ± 0.1). Tumour size was 3.3 ± 0.2 cm (range 1-13 cm, median 3 cm) with mean number of lesions 1.9 ± 0.1 (range 1-7). Mean model for the end stage liver disease score: 11 ± 0.4; cancer of the liver Italian program score: 1.3 ± 0.1. Survival post-TACE (excluding those underwent orthotopic liver transplantation) was 12 ± 0.3 months. By multivariate analysis, tumour size (HR = 1.37, 95% CI: 1.11-1.68, P = 0.003), hypovascularity (HR = 12.62, 95% CI: 1.79-88.92, P = 0.01) and elevated international normalized ratio (HR = 1.46, 95% CI: 1.10-1.92 P = 0.008) are shown to be significant risk factors for increased mortality. Conclusion: TACE therapy leads to a mean survival of 12 months in patients not receiving orthotopic liver transplantation. Tumour size, hypovascularity on imaging, and elevated international normalized ratio are predictors of increased mortality after TACE therapy for HCC.

Original languageEnglish
Pages (from-to)393-400
Number of pages8
JournalAlimentary Pharmacology and Therapeutics
Volume26
Issue number3
DOIs
StatePublished - Aug 2007

Fingerprint

Hepatocellular Carcinoma
International Normalized Ratio
Liver Transplantation
Survival
Mortality
Neoplasms
End Stage Liver Disease
Liver Neoplasms
Liver Diseases
Multivariate Analysis
Demography
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Predictors of outcome in patients with unresectable hepatocellular carcinoma receiving transcatheter arterial chemoembolization. / Shen, H.; Agarwal, D.; Qi, R.; Chalasani, Naga; Liangpunsakul, Suthat; Lumeng, L.; Yoo, H.; Kwo, P.

In: Alimentary Pharmacology and Therapeutics, Vol. 26, No. 3, 08.2007, p. 393-400.

Research output: Contribution to journalArticle

@article{5ddac713880c4c47a515c98ee294d384,
title = "Predictors of outcome in patients with unresectable hepatocellular carcinoma receiving transcatheter arterial chemoembolization",
abstract = "Background: Transcatheter arterial chemoembolization (TACE) has been shown to improve survival in patients with unresectable hepatocellular carcinoma (HCC). Aim: To identify pretreatment factors that predicts increased mortality in HCC patients receiving TACE. Methods: Retrospective review of all patients who underwent TACE for HCC from January 1999 to November 2004. Patient demographics, aetiology of liver disease, laboratory and imaging data regarding tumour characteristics were obtained. Results: Eighty-eight patients (57 ± 1 years age) received 1-4 sessions of TACE (1.4 ± 0.1). Tumour size was 3.3 ± 0.2 cm (range 1-13 cm, median 3 cm) with mean number of lesions 1.9 ± 0.1 (range 1-7). Mean model for the end stage liver disease score: 11 ± 0.4; cancer of the liver Italian program score: 1.3 ± 0.1. Survival post-TACE (excluding those underwent orthotopic liver transplantation) was 12 ± 0.3 months. By multivariate analysis, tumour size (HR = 1.37, 95{\%} CI: 1.11-1.68, P = 0.003), hypovascularity (HR = 12.62, 95{\%} CI: 1.79-88.92, P = 0.01) and elevated international normalized ratio (HR = 1.46, 95{\%} CI: 1.10-1.92 P = 0.008) are shown to be significant risk factors for increased mortality. Conclusion: TACE therapy leads to a mean survival of 12 months in patients not receiving orthotopic liver transplantation. Tumour size, hypovascularity on imaging, and elevated international normalized ratio are predictors of increased mortality after TACE therapy for HCC.",
author = "H. Shen and D. Agarwal and R. Qi and Naga Chalasani and Suthat Liangpunsakul and L. Lumeng and H. Yoo and P. Kwo",
year = "2007",
month = "8",
doi = "10.1111/j.1365-2036.2007.03395.x",
language = "English",
volume = "26",
pages = "393--400",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Predictors of outcome in patients with unresectable hepatocellular carcinoma receiving transcatheter arterial chemoembolization

AU - Shen, H.

AU - Agarwal, D.

AU - Qi, R.

AU - Chalasani, Naga

AU - Liangpunsakul, Suthat

AU - Lumeng, L.

AU - Yoo, H.

AU - Kwo, P.

PY - 2007/8

Y1 - 2007/8

N2 - Background: Transcatheter arterial chemoembolization (TACE) has been shown to improve survival in patients with unresectable hepatocellular carcinoma (HCC). Aim: To identify pretreatment factors that predicts increased mortality in HCC patients receiving TACE. Methods: Retrospective review of all patients who underwent TACE for HCC from January 1999 to November 2004. Patient demographics, aetiology of liver disease, laboratory and imaging data regarding tumour characteristics were obtained. Results: Eighty-eight patients (57 ± 1 years age) received 1-4 sessions of TACE (1.4 ± 0.1). Tumour size was 3.3 ± 0.2 cm (range 1-13 cm, median 3 cm) with mean number of lesions 1.9 ± 0.1 (range 1-7). Mean model for the end stage liver disease score: 11 ± 0.4; cancer of the liver Italian program score: 1.3 ± 0.1. Survival post-TACE (excluding those underwent orthotopic liver transplantation) was 12 ± 0.3 months. By multivariate analysis, tumour size (HR = 1.37, 95% CI: 1.11-1.68, P = 0.003), hypovascularity (HR = 12.62, 95% CI: 1.79-88.92, P = 0.01) and elevated international normalized ratio (HR = 1.46, 95% CI: 1.10-1.92 P = 0.008) are shown to be significant risk factors for increased mortality. Conclusion: TACE therapy leads to a mean survival of 12 months in patients not receiving orthotopic liver transplantation. Tumour size, hypovascularity on imaging, and elevated international normalized ratio are predictors of increased mortality after TACE therapy for HCC.

AB - Background: Transcatheter arterial chemoembolization (TACE) has been shown to improve survival in patients with unresectable hepatocellular carcinoma (HCC). Aim: To identify pretreatment factors that predicts increased mortality in HCC patients receiving TACE. Methods: Retrospective review of all patients who underwent TACE for HCC from January 1999 to November 2004. Patient demographics, aetiology of liver disease, laboratory and imaging data regarding tumour characteristics were obtained. Results: Eighty-eight patients (57 ± 1 years age) received 1-4 sessions of TACE (1.4 ± 0.1). Tumour size was 3.3 ± 0.2 cm (range 1-13 cm, median 3 cm) with mean number of lesions 1.9 ± 0.1 (range 1-7). Mean model for the end stage liver disease score: 11 ± 0.4; cancer of the liver Italian program score: 1.3 ± 0.1. Survival post-TACE (excluding those underwent orthotopic liver transplantation) was 12 ± 0.3 months. By multivariate analysis, tumour size (HR = 1.37, 95% CI: 1.11-1.68, P = 0.003), hypovascularity (HR = 12.62, 95% CI: 1.79-88.92, P = 0.01) and elevated international normalized ratio (HR = 1.46, 95% CI: 1.10-1.92 P = 0.008) are shown to be significant risk factors for increased mortality. Conclusion: TACE therapy leads to a mean survival of 12 months in patients not receiving orthotopic liver transplantation. Tumour size, hypovascularity on imaging, and elevated international normalized ratio are predictors of increased mortality after TACE therapy for HCC.

UR - http://www.scopus.com/inward/record.url?scp=34447307982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447307982&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2007.03395.x

DO - 10.1111/j.1365-2036.2007.03395.x

M3 - Article

VL - 26

SP - 393

EP - 400

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 3

ER -